Order Intake, Study Completion and Collection Risks in the Pharmaceutical Clinical Research Support Business
First written in FY2016. 12 of 21 entries say "Materialised", first in FY2021-Q2. Latest entry: FY2024.
Soiken Holdings moved to the "Worse" side of this theme in 2021.
0 other companies' latest entry also says "Materialised".
- FY2024MaterialisedAnnual report
「In the pharmaceutical clinical research support business, revenue included ¥89 million in fees for commissioned support services, primarily for physician-led clinical research in the diabetes field, down 74.8% year on year. Orders received were ¥1 million, down 99.4% year on year, and there was no order backlog at the end of the consolidated fiscal year because the pharmaceutical clinical research support business had been discontinued.」
The deterioration in the order environment and decline in accumulated future revenue continued, with orders received of ¥1 million and no order backlog. The risks associated with orders received and completion of research have materialised as the termination of the business following its discontinuation. - FY2024-Q3MaterialisedAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥102 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, down 59.0% year on year. Orders received totaled ¥55 million, down 64.7% year on year, while the order backlog at the end of the third quarter of the current consolidated fiscal year was ¥41 million, down 71.1% from the end of the same period of the previous year.」
In the pharmaceutical clinical research support business, lower revenue, a decline in orders received and a substantial decrease in the order backlog have continued, with risks related to the order environment and the accumulation of future revenue continuing to be reflected in results. - FY2024-Q2MaterialisedAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥110 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, down 27.1% year on year. Orders received totaled ¥63 million, down 12.4% year on year, while the order backlog at the end of the second quarter of the current consolidated fiscal year was ¥42 million, down 73.3% from the end of the same period of the previous year.」
In the pharmaceutical clinical research support business, risks related to the order environment and the accumulation of future revenue continue to be reflected in results as lower revenue, a decline in orders received and a substantial decrease in the order backlog. - FY2024-Q1MaterialisedAnnual report
「We recognized revenue of ¥43 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, down 38.1% year on year. Orders received totaled ¥18 million, down 57.3% year on year, while the order backlog at the end of the first quarter of the current consolidated fiscal year was ¥63 million, down 69.6% from the end of the same period of the previous year.」
Revenue, order intake and the order backlog in the clinical research support business declined significantly, and risks related to the order environment and the accumulation of future revenue continue to be reflected in actual results. - FY2023MaterialisedAnnual report
「To provide for future losses related to order contracts, the company recognized the estimated amount of losses related to order contracts at the end of the fiscal year.」
The company recognized a provision for losses on order contracts of ¥27.207 million for future losses related to order contracts. The previously identified risks related to orders, study completion and profitability have materialized as an accounting provision. - FY2023-Q3MaterialisedAnnual report
「We recognized revenue of ¥250 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, up 14.4% year on year. Orders received totaled ¥158 million, down 39.8% year on year, while the order backlog at the end of the third quarter of the current consolidated fiscal year was ¥144 million, down 57.5% from the end of the same period of the previous year.」
Although revenue increased in the clinical research support business, order intake and the order backlog declined significantly, and risks related to the order environment and the accumulation of future revenue continue to be reflected in actual results. - FY2023-Q2MaterialisedAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥151 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, up 21.5% year on year. Orders received totaled ¥72 million, down 64.0% year on year, while the order backlog at the end of the second quarter of the current consolidated fiscal year was ¥158 million, down 57.7% from the end of the same period of the previous year.」
Although revenue increased, the significant decline in order intake and the order backlog was reflected in actual results, and risks related to the order environment and the accumulation of future revenue continue. - FY2023-Q1MaterialisedAnnual report
「Within the biological evaluation systems business, the pharmaceutical clinical research support business recognized revenue of ¥70 million from commissions for supporting mainly investigator-initiated clinical research in the diabetes field, up 11.2% year on year. Orders received totaled ¥43 million, down 66.7% year on year, while the order backlog at the end of the first quarter of the current consolidated fiscal year was ¥210 million, down 42.4% from the end of the same period of the previous year.」
Although revenue increased in the clinical research support business, order intake and the order backlog declined significantly, and risks related to the order environment and the accumulation of future revenue continue to be reflected in actual results. - FY2022-Q3MaterialisedAnnual report
「Within the biological evaluation systems business, the clinical research support business recognized ¥218 million in revenue from contract fees and other income mainly for support services for physician-initiated clinical studies in the diabetes field, down 26.3% year on year. Order intake was ¥263 million, down 11.0% year on year, while the order backlog at the end of the third quarter was ¥340 million, down 16.1% from the end of the same period of the previous year. Accordingly, the biological evaluation systems business reported revenue of ¥336 million, down 31.0% year on year, and an operating loss of ¥18 million, compared with operating profit of ¥15 million in the same period of the previous year.」
Revenue, order intake and the order backlog in the clinical research support business declined, and the biological evaluation systems business recorded an operating loss. Risks related to the deteriorating order environment and declining order backlog continue to be reflected in actual results. - FY2022-Q1MaterialisedAnnual report
「Regarding the impact of the spread of COVID-19, the biological evaluation systems business has seen a decline in orders due to the postponement and cancellation of new projects. However, as the business accounts for a small proportion of consolidated results, its impact on the Group's results is currently minor.」
The company states that COVID-19 has in fact led to the postponement and cancellation of new projects and a trend toward lower orders in the biological evaluation systems business. - FY2021-Q3MaterialisedAnnual report
「In this business, the fixed-cost burden included in cost of sales increased in the evaluation testing business due to the decline in the order backlog, while the clinical research support business saw an increase in small-scale projects with low profitability. As a result, the cost-of-sales ratio rose and operating expenses increased. Accordingly, the biological evaluation systems business reported revenue of ¥487 million, up 2.4% year on year, and an operating loss of ¥15 million, compared with operating profit of ¥58 million in the same period of the previous year.」
The decline in the order backlog increased the fixed-cost burden, while the increase in small-scale projects with low profitability raised the cost-of-sales ratio and operating expenses, resulting in an operating loss for the biological evaluation systems business. - FY2021-Q2MaterialisedAnnual report
「Within the biological evaluation systems business, the clinical research support business recognized ¥206 million in revenue from contract fees and other income mainly for support services for physician-initiated clinical studies in the diabetes field, down 10.3% year on year. Order intake was ¥204 million, up 210.4% year on year, while the order backlog at the end of the second quarter was ¥404 million, down 6.7% from the end of the same period of the previous year. In this business, the cost-of-sales ratio rose and operating expenses increased in both the evaluation testing business and the clinical research support business, mainly because the decline in the order backlog increased the fixed-cost burden included in cost of sales.」
Although order intake increased, the order backlog declined, and the higher fixed-cost burden increased the cost-of-sales ratio and operating expenses. The biological evaluation systems business, including the clinical research support business, recorded an operating loss. - FY2021-Q1Orders received increased, but the order backlog declinedAnnual report
「Order intake was ¥96 million, up 153.5% year on year, while the order backlog at the end of the first quarter was ¥350 million, down 26.6% from the end of the same period of the previous year.」
The clinical research support business posted higher order intake but a lower order backlog. Although there has been progress in new orders, risks related to the accumulation of future revenue remain. - FY2020RestatedAnnual report
「Competition from other companies and deterioration in the order environment may prevent contracted work from increasing as expected by the Group, which could adversely affect the Group's future results.」
For the clinical research support business, the company continues to disclose risks related to competition, the order environment, study discontinuations and cancellations during contracts, revenue recognition and collection of receivables. - FY2020-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The company states that there have been no material changes to the order intake, study completion and collection risks in the clinical research support business. - FY2020-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The company states that there have been no material changes to the order intake, study completion and collection risks in the clinical research support business. - FY2019-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The company states in a consolidated disclosure that there have been no material changes to the order intake, study completion and collection risks in the clinical research support business. - FY2019-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The company states in a consolidated disclosure that there have been no material changes to the order intake, study completion and collection risks in the clinical research support business. - FY2019-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The company states in a consolidated disclosure that there have been no material changes to the order intake, study completion and collection risks in the clinical research support business. - FY2018RestatedAnnual report
「However, competition from other companies and deterioration in the order environment may prevent contracted work from increasing as expected by the Group, which could adversely affect the Group's future results.」
For the clinical research support business, the company continues to disclose risks related to competition, the order environment, strengthening its business platform, study discontinuations and cancellations during contracts, revenue recognition and collection of receivables. - FY2016First statedAnnual report
「Competition from other companies and deterioration in the order environment may prevent contracted work from increasing as expected by the Group, which could adversely affect the Group's future results.」
This includes failure to achieve market expansion targets, stagnation in new orders, shortages of medical institution networks and personnel, guideline revisions, cancellations during contracts, failure to achieve target case numbers, and collection of receivables.